Since 1973 the World Symposia on Pulmonary Hypertension (WSPH) proceedings have
summarised the scientific advances and future needs in this field through the efforts of …

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Pulmonary hypertension remained an unexplained intractable disease with poor prognosis.
In the last 2 decades, however, the diagnosis and treatment methods for this disease …

Pulmonary hypertension (PH) describes a group of severe pulmonary vascular disorders
characterized by elevated mean pulmonary arterial pressure (mPAP) at rest. 1 The World …

The assessment of objective measurement of cardiopulmonary status has helped us
achieve better clinical outcomes for patients and develop new therapies through to the point …

Purpose: Hypertension is a major risk factor for cardiovascular diseases and stroke, and it
requires lifelong medication. This study aimed to investigate the factors impacting on Health …

Background Anxiety and depression are frequent disorders in patients with pulmonary
arterial hypertension (PAH), but despite this only less than one-fourth of them is treated. Our …

Pulmonary arterial hypertension (PAH) is a severe disease characterised by increased
pulmonary vascular resistance, which leads to restricted pulmonary arterial blood flow and …

Patients with comorbidities are often excluded from clinical trials, limiting the evidence base
for pulmonary arterial hypertension (PAH)-specific therapies. This review aims to discuss the …

Health-related quality of life (HRQoL) scores assess symptom burden in pulmonary arterial
hypertension (PAH) but data regarding their role in prognostication and risk stratification are …